From Wikipedia, the free encyclopedia
This article or section needs
sources or references that appear in reliable, third-party publications. Alone,
primary sources and sources affiliated with the subject of the article are not sufficient for an accurate encyclopedia article. Please include more appropriate
citations from
reliable sources.
This article has been tagged since December 2006.Tercica, Inc., is a biopharmaceutical company based in Brisbane, California, USA. It is the current developer of Increlex™ (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Tercica has applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency (Primary IGFD), which is chracterized by growth faiulre, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.
Tercica licensed rights to develop, manufacture, and market Increlex from Genentech, Inc. Increlex is currently in Phase III clinical trials to evaluate the safety and efficacy of Increlex in children with Primary IGFD.
[edit] See also
[edit] External links
